travis holly

FDA advisory panel recommendations to allow compounding of peptides like BPC-157 and KPV create a new regulatory pathway for affordable peptide therapies, enabling platforms like Hims & Hers to expand treatment menus at low price points ($20-30/month) and drive subscriber growth through accessibility rather than high ARPU.

The FDA's review of peptide compounding eligibility represents a structural policy shift that could legitimize direct-to-consumer peptide therapies outside traditional insurance reimbursement, benefiting platforms that control the end-to-end experience from diagnostics to fulfillment.

Hims & Hers is shifting from transactional prescriptions to an AI-powered platform where lab data feeds conversational AI and providers to create personalized, compounded treatment plans with transparent pricing, creating a data flywheel that increases platform value with each additional specialty and subscriber.